His primary areas of study are Transplantation, Internal medicine, Kidney transplantation, Pharmacology and Urology. His Transplantation study incorporates themes from Kidney and Immunology. His research integrates issues of Gastroenterology, Placebo and Endocrinology in his study of Internal medicine.
Surgery covers Klemens Budde research in Kidney transplantation. His Surgery research is multidisciplinary, incorporating elements of Immunosuppression and Incidence. His study in Urology is interdisciplinary in nature, drawing from both Renal function, Survival rate, Autosomal dominant polycystic kidney disease, Basiliximab and Everolimus.
His primary scientific interests are in Transplantation, Internal medicine, Kidney transplantation, Urology and Surgery. His studies in Transplantation integrate themes in fields like Immunosuppression, Kidney, Pharmacology and Intensive care medicine. Klemens Budde has included themes like Gastroenterology, Endocrinology and Oncology in his Internal medicine study.
His Kidney transplantation research incorporates elements of Clinical trial, Randomized controlled trial, Retrospective cohort study, Immunology and Ciclosporin. The various areas that Klemens Budde examines in his Urology study include Calcineurin, Renal function, Regimen, Tacrolimus and Everolimus. Surgery is often connected to Kidney disease in his work.
Klemens Budde mainly focuses on Internal medicine, Kidney transplantation, Transplantation, Urology and Renal function. His work in Internal medicine tackles topics such as Gastroenterology which are related to areas like Antibody. His study on Kidney transplantation is covered under Kidney.
Transplantation is a subfield of Surgery that Klemens Budde investigates. Klemens Budde combines subjects such as Creatinine and Nephrectomy with his study of Surgery. His research in Urology intersects with topics in Tuberous sclerosis, Tacrolimus, Biopsy, Everolimus and Proteinuria.
Klemens Budde mostly deals with Kidney transplantation, Transplantation, Internal medicine, Urology and Intensive care medicine. In the subject of general Kidney transplantation, his work in Antibody mediated rejection is often linked to Outcome, thereby combining diverse domains of study. His Transplantation study combines topics in areas such as Diabetes mellitus, Immunosuppression, Disease and Quality of life.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Oncology. The concepts of his Urology study are interwoven with issues in Angiomyolipoma, Renal function, Tuberous sclerosis, Tacrolimus and Everolimus. His Renal function research includes themes of Clinical endpoint, Proteinuria and Mycophenolic acid.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
John J Bissler;J Christopher Kingswood;Elżbieta Radzikowska;Bernard A Zonnenberg.
The Lancet (2013)
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
Duska Dragun;Dominik N. Müller;Jan Hinrich Bräsen;Lutz Fritsche.
The New England Journal of Medicine (2005)
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus.
F. Vincenti;S. Friman;E. Scheuermann;L. Rostaing.
American Journal of Transplantation (2007)
Everolimus in patients with autosomal dominant polycystic kidney disease.
Gerd Walz;Klemens Budde;Marwan Mannaa;Jens Nürnberger.
The New England Journal of Medicine (2010)
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Klemens Budde;Thomas Becker;Wolfgang Arns;Claudia Sommerer.
The Lancet (2011)
Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.
Nils Lachmann;Paul I. Terasaki;Klemens Budde;Lutz Liefeldt.
CC chemokine receptor 5 and renal-transplant survival
Michael Fischereder;Bruno Luckow;Berthold Hocher;Rudolf P Wüthrich.
The Lancet (2001)
First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients
Klemens Budde;Robert L. Schmouder;Reinhard Brunkhorst;Bjorn Nashan.
Journal of The American Society of Nephrology (2002)
Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial
Teun van Gelder;Helio Tedesco Silva;Johan W. de Fijter;Klemens Budde.
Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction.
F Diekmann;K Budde;F Oppenheimer;L Fritsche.
American Journal of Transplantation (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: